Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients

INTRODUCTION: Meningiomas are hormonally sensitive tumors that occur disproportionately among women with breast cancer. We compared the risk of incident meningioma among patients initiating aromatase inhibitors (AIs) versus tamoxifen. METHODS: Using the TriNetX Global Collaborative Network (181 healthcare organizations), we identified adults with breast cancer recorded during 2010-2015 who initiated anastrozole, letrozole, or exemestane versus tamoxifen, without exposure to the alternate endocrine therapy class. Cohorts were matched 1:1 on 27 covariates. Incident meningioma was assessed at 1, 2, and 3 years using risk estimates and Cox proportional hazards models. RESULTS: After matching, 23,204 patients were included per cohort; 23,110 AI users and 23,114 tamoxifen users without prior meningioma were included in the outcome analyses. Meningioma risk was higher with AIs at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056-3.227), 2 years (2.64 vs 1.56; HR 1.705, 95% CI 1.129-2.574), and 3 years (3.29 vs 2.29; HR 1.449, 95% CI 1.021-2.058). Absolute risk differences were 0.69, 1.08, and 1.00 per 1,000, respectively. CONCLUSION: AI initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma than tamoxifen, with a small absolute excess. These findings should not alter endocrine therapy selection but may inform evaluation of new dural-based lesions in AI users.

Authors

Institutions

Publication Details

Journal
Cancer Causes & Control
Published
2026-11-18
DOI
https://doi.org/10.1007/s10552-026-02277-3
Primary Topic
Meningioma and schwannoma management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients

Brandon Peter Lucke-Wold, Jeremiah Hilkiah Wijaya, Made Agus Mahendra Inggas, Soni Roy Kurniawan Hulu et al.
1 links
Cancer Causes & Control
Meningioma and schwannoma management
article

Aromatase inhibitors versus tamoxifen and the risk of incident intracranial meningioma: a propensity score matching analysis of 46,408 patients

Brandon Peter Lucke-Wold, Jeremiah Hilkiah Wijaya, Made Agus Mahendra Inggas, Soni Roy Kurniawan Hulu, Vivien Puspitasari
article en

Abstract

INTRODUCTION: Meningiomas are hormonally sensitive tumors that occur disproportionately among women with breast cancer. We compared the risk of incident meningioma among patients initiating aromatase inhibitors (AIs) versus tamoxifen. METHODS: Using the TriNetX Global Collaborative Network (181 healthcare organizations), we identified adults with breast cancer recorded during 2010-2015 who initiated anastrozole, letrozole, or exemestane versus tamoxifen, without exposure to the alternate endocrine therapy class. Cohorts were matched 1:1 on 27 covariates. Incident meningioma was assessed at 1, 2, and 3 years using risk estimates and Cox proportional hazards models. RESULTS: After matching, 23,204 patients were included per cohort; 23,110 AI users and 23,114 tamoxifen users without prior meningioma were included in the outcome analyses. Meningioma risk was higher with AIs at 1 year (1.51 vs 0.82 per 1,000; HR 1.846, 95% CI 1.056-3.227), 2 years (2.64 vs 1.56; HR 1.705, 95% CI 1.129-2.574), and 3 years (3.29 vs 2.29; HR 1.449, 95% CI 1.021-2.058). Absolute risk differences were 0.69, 1.08, and 1.00 per 1,000, respectively. CONCLUSION: AI initiation was associated with a modestly higher but progressively attenuating relative risk of meningioma than tamoxifen, with a small absolute excess. These findings should not alter endocrine therapy selection but may inform evaluation of new dural-based lesions in AI users.

Cancer Causes & ControlVol. 37(12)
Rutgers, The State University of New Jersey (US), Pelita Harapan University (ID), University of Arizona (US), Rutgers New Jersey Medical School (US), Taipei Medical University (TW)
Good health and well-being
Meningioma and schwannoma management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon